In May 2023, Kenvue officially spun off from Johnson & Johnson, marking its debut as an independent company through an initial public offering on the New York Stock Exchange, raising approximately $3.8 billion and establishing it as the world's largest pure-play consumer health company. This separation allowed Kenvue to focus solely on consumer health brands, divesting from J&J's pharmaceutical and medical device segments, and was driven by a strategic move to unlock value for shareholders. In August 2023, Kenvue completed its full separation from J&J, including the transfer of assets and liabilities, which involved complex legal and operational restructuring. More recently, in early 2024, the company faced a significant legal development when a U.S. court ruled on talc-related lawsuits inherited from J&J, potentially impacting its financial reserves as reported in Reuters coverage. Additionally, in late 2023, Kenvue announced a major sustainability initiative, committing to reduce greenhouse gas emissions by 50% by 2030, aligning with global environmental trends.

Kenvue is a leading consumer health company headquartered in Skillman, New Jersey, with a portfolio of iconic brands including Tylenol, Neutrogena, Listerine, and Band-Aid, serving over a billion consumers worldwide. Formed from the consumer health division of Johnson & Johnson, it positions itself as an innovator in everyday health solutions, emphasizing science-backed products for self-care, skin health, and essential health needs. With approximately 22,000 employees and operations in more than 165 countries, Kenvue generates annual revenues exceeding $15 billion, focusing on categories like over-the-counter medicines, oral care, and baby care. The company's current positioning emphasizes digital transformation and e-commerce growth, leveraging its heritage to build trust while adapting to modern consumer demands for personalized and sustainable products. This makes Kenvue an attractive employer for young professionals interested in blending healthcare innovation with consumer-facing technology and sales roles.

Kenvue's tech department excels in leveraging data analytics and AI to enhance supply chain efficiency, using proprietary platforms for predictive inventory management that reduce waste in manufacturing processes. The company invests heavily in digital health tools, such as mobile apps for personalized skincare recommendations powered by machine learning, which integrate with IoT devices for real-time consumer insights. In the consumer health industry, Kenvue is well-positioned for innovation due to its focus on digital therapeutics and e-commerce integrations, outpacing competitors in adopting cloud-based solutions for global operations. Career development in tech roles is highly regarded, with structured mentorship programs and rotations across functions, as highlighted in employee reviews on Glassdoor. Salaries for software engineers and IT professionals are competitive, averaging around $120,000-$150,000 annually for mid-level positions, according to data from levels.fyi, though work-life balance can vary by department.

Kenvue faces challenges from intense competition with giants like Procter & Gamble and Unilever, who often have broader product diversification and stronger marketing budgets, potentially eroding market share in key segments like oral care. Supply chain vulnerabilities, exacerbated by global disruptions, pose limitations, as seen in recent raw material shortages affecting production timelines. Opportunities lie in expanding into emerging markets such as Asia-Pacific, where rising middle-class populations drive demand for premium health products, and in innovating sustainable packaging to appeal to eco-conscious consumers. Threats include regulatory pressures, particularly around product safety claims and environmental compliance, which could lead to costly recalls or fines. Additionally, economic downturns may shift consumer spending toward generic alternatives, intensifying price wars in the over-the-counter medicine space.